Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

714 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, León L, Lázaro M, Grande C, Mel JR, Ramos M, Salgado M, Casal J. Vázquez S, et al. Among authors: salgado m. Anticancer Drugs. 2007 Nov;18(10):1201-6. doi: 10.1097/CAD.0b013e328273bbce. Anticancer Drugs. 2007. PMID: 17893521 Clinical Trial.
Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.
Feliu J, Firvida JL, Castro J, Madroñal C, Rodríguez-Jaráiz A, Salgado M, Belda-Iniesta C, Casado E, García-Mata J, González-Barón M; Oncopaz Cooperative Group. Feliu J, et al. Among authors: salgado m. Cancer Chemother Pharmacol. 2009 Feb;63(3):403-9. doi: 10.1007/s00280-008-0749-z. Epub 2008 Apr 9. Cancer Chemother Pharmacol. 2009. PMID: 18398610 Clinical Trial.
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Fernandez-Plana J, et al. Among authors: salgado m. BMC Cancer. 2014 Nov 22;14:865. doi: 10.1186/1471-2407-14-865. BMC Cancer. 2014. PMID: 25417182 Free PMC article. Clinical Trial.
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Fernández A, et al. Among authors: salgado m. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. BMC Cancer. 2018. PMID: 30497432 Free PMC article.
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R, Mata E, González E, Juez I, Alonso V, Iranzo P, Martínez NP, López C, Cabrera JM, Safont MJ, Ruiz-Casado A, Salgado M, González B, Escudero P, Rivera F, Pericay C. Vera R, et al. Among authors: salgado m. Int J Colorectal Dis. 2020 Apr;35(4):739-746. doi: 10.1007/s00384-020-03509-x. Epub 2020 Feb 15. Int J Colorectal Dis. 2020. PMID: 32062727
Colorectal cancer prognosis twenty years later.
Bujanda L, Sarasqueta C, Hijona E, Hijona L, Cosme A, Gil I, Elorza JL, Asensio JI, Larburu S, Enríquez-Navascués JM, Jover R, Balaguer F, Llor X, Bessa X, Andreu M, Paya A, Castells A; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Bujanda L, et al. World J Gastroenterol. 2010 Feb 21;16(7):862-7. doi: 10.3748/wjg.v16.i7.862. World J Gastroenterol. 2010. PMID: 20143465 Free PMC article.
714 results